Have a personal or library account? Click to login
Serum total antioxidant capacity and enzymatic defence of dogs with chronic heart failure and atrial fibrillation: a preliminary study Cover

Serum total antioxidant capacity and enzymatic defence of dogs with chronic heart failure and atrial fibrillation: a preliminary study

Open Access
|Jul 2020

References

  1. Atkins C., Bonagura J., Ettinger S., Fox P., Gordon S., Häggström J., Hamlin R., Keene B., Luis-Fuentes V., Stepien R.: Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med 2009, 23, 1142–1150.
  2. Brigelius-Flohé R., Maiorino M.: Glutathione peroxidases. Biochim Biophys Acta 2013, 1830, 3289–3303.
  3. Castro P.F., Díaz-Araya G., Nettle D., Corbalán R., Pérez O., Nazzal C., Larrain G., Lavandero S.: Effects of early decrease in oxidative stress after medical therapy in patients with class IV congestive heart failure. Am J Cardiol 2002, 89, 236–239.
  4. Cornell C.C., Kittleson M.D., Della Torre P., Häggström J., Lombard C.W., Pedersen H.D., Vollmar A., Wey A.: Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med 2004, 18, 311–321.
  5. Dieterich S., Bieligk U., Beulich K., Hasenfuss G., Prestle J.: Gene expression of antioxidative enzymes in the human heart: increased expression of catalase in the end-stage failing heart. Circulation 2000, 101, 33–39.
  6. Dong L.Y., Li S., Zhen Y.L., Wang Y.N., Shao X., Luo Z.G.: Cardioprotection of vitexin on myocardial ischemia/reperfusion injury in rat via regulating inflammatory cytokines and MAPK pathway. Am J Chin Med 2013, 41, 1251–1266.
  7. Dukes-McEwan J., Borgarelli M., Tidholm A., Vollmar A.C., Häggström J.: ESVC taskforce for canine dilated cardiomyopathy: proposed guidelines for the diagnosis of canine idiopathic dilated cardiomyopathy. J Vet Cardiol 2003, 5, 7–19.
  8. Ettinger S.J., Suter P.F.: The recognition of cardiac disease and congestive heart failure. In: Canine Cardiology edited by S.J. Ettinger, P.F. Suter, W.B. Saunders, Philadelphia, 1970, p. 5.
  9. Flores-Mateo G., Carrillo-Santisteve P., Elosua R., Guallar E., Marrugat J., Bleys J., Covas M.I.: Antioxidant enzyme activity and coronary heart disease: meta-analyses of observational studies. Am J Epidemiol 2009, 170, 135–147.
  10. Freeman L.M., Brown D.J., Rush J.E.: Antioxidant status in dogs with idiopathic dilated cardiomyopathy. J Nutr 1998, 128, 2768S–2770S.
  11. Freeman L.M., Rush J.E., Milbury P.E., Blumberg J.B.: Antioxidant status and biomarkers of oxidative stress in dogs with congestive heart failure. J Vet Intern Med 2005, 19, 537–541.
  12. Galeotti T., Borrello S., Masotti L.: Oxy-radical sources, scavenger systems and membrane damage in cancer cells. In: Oxygen Radicals: Systemic events and disease processes edited by D.K. Das, W.B. Essman, Karger, Basel, 1990, pp. 129–148.
  13. Guglielmini C., Chetboul V., Pietra M., Pouchelon J.L., Capucci A., Cipone M.: Influence of left atrial enlargement and body weight on the development of atrial fibrillation: retrospective study on 205 dogs. Vet J 2000, 160, 235–241.
  14. Hetyey C.S., Manczur F., Dudás-Györki Z., Reiczigel J., Ribiczey P., Vajdovich P., Vörös K.: Plasma antioxidant capacity in dogs with naturally occurring heart diseases. J Vet Med A Physiol Pathol Clin Med 2007, 54, 36–39.
  15. Kodydková J., Vávrová L., Kocík M., Žák A.: Human catalase, its polymorphisms, regulation and changes of its activity in different diseases. Folia Biol (Praha) 2014, 60, 153–167.
  16. Krupa W., Rozwodowska M., Sielski S., Czarnecka-Żaba E., Fabiszak T., Drewa G., Kasprzak M., Kubica J.: Influence of cardiac resynchronization therapy on oxidative stress markers in patients with chronic heart failure. Cardiol J 2014, 21, 576–582.
  17. Marklund S.L.: Human copper-containing superoxide dismutase of high molecular weight. Proc Natl Acad Sci USA 1982, 79, 7634–7638.
  18. Mattera R., Benvenuto M., Giganti M.G., Tresoldi I., Pluchinotta F.R., Bergante S., Tettamanti G., Masuelli L., Manzari V., Modesti A., Bei R.: Effects of polyphenols on oxidative stress-mediated injury in cardiomyocytes. Nutrients 2017, 20, 523.
  19. Menaut P., Bélanger M.C., Beauchamp G., Ponzio N.M., Moïse N.S.: Atrial fibrillation in dogs with and without structural or functional cardiac disease: a retrospective study of 109 cases. J Vet Cardiol 2005, 7, 75–83.
  20. Noszczyk-Nowak A., Michałek M., Kałuża E., Cepiel A., Pasławska U.: Prevalence of arrhythmias in dogs examined between 2008 and 2014. J Vet Res 2017, 61, 103–110.
  21. Prasad K., Gupta J.B., Kalra J., Lee P., Mantha S.V., Bharadwaj B.: Oxidative stress as a mechanism of cardiac failure in chronic volume overload in canine model. J Mol Cell Cardiol 1996, 28, 375–385.
  22. Rapti K., Diokmetzidou A., Kloukina I., Milner D.J., Varela A., Davos C.H., Capetanaki Y.: Opposite effects of catalase and MnSOD ectopic expression on stress induced defects and mortality in the desmin deficient cardiomyopathy model. Free Radic Biol Med 2017, 110, 206–218.
  23. Rubio C.P., Hernández-Ruiz J., Martinez-Subiela S., Tvarijonaviciute A., Ceron J.J.: Spectrophotometric assays for total antioxidant capacity (TAC) in dog serum: an update. BMC Vet Res 2016, 12, 166.
  24. Sawyer D.B.: Oxidative stress in heart failure: what are we missing? Am J Med Sci 2011, 342, 120–124.
  25. Svete A.N., Verk B., Seliškar A., Tomsič K., Križman P.J., Petrič A.D.: Plasma coenzyme Q10 concentration, antioxidant status, and serum N-terminal pro-brain natriuretic peptide concentration in dogs with various cardiovascular diseases and the effect of cardiac treatment on measured variables. Am J Vet Res 2017, 78, 447–457.
  26. Tsutsui H., Kinugawa S., Matsushima S.: Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol 2011, 301, 2181–2190.
  27. Verk B., Nemec Svete A., Salobir J., Rezar V., Domanjko-Petrič A.: Markers of oxidative stress in dogs with heart failure. J Vet Diagn Invest 2017, 29, 636–644.
  28. Wang J., He D., Zhang Q., Han Y., Jin S., Qi F.: Resveratrol protects against Cisplatin-induced cardiotoxicity by alleviating oxidative damage. Cancer Biother Radiopharm 2009, 24, 675–680.
  29. Yoo S., Aistrup G., Shiferaw Y., Ng J., Mohler P.J., Hund T.J., Waugh T., Browne S., Gussak G., Gilani M., Knight B.P., Passman R., Goldberger J.J., Wasserstrom J.A., Arora R.: Oxidative stress creates a unique, CaMKII-mediated substrate for atrial fibrillation in heart failure. JCI Insight 2018, 2, e120728.
Language: English
Page range: 439 - 444
Submitted on: Nov 7, 2019
Accepted on: Jun 26, 2020
Published on: Jul 28, 2020
Published by: National Veterinary Research Institute in Pulawy
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2020 Marcin Michałek, Aleksandra Tabiś, Agnieszka Noszczyk-Nowak, published by National Veterinary Research Institute in Pulawy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.